ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Health Disparities Center Describes “Think Tank” Projects For Policy Change.

April 27, 2001

Missouri, Michigan Program As For Comprehensive Review

September 23, 1977

OMB Backs Down, May Release New Construction Funds For UCLA, Salk, NYU

April 25, 1975

More Bad News For Estrogen: Increased Ovarian Cancer Risk

July 19, 2002

Project Enlists PC Users In Quest For Cancer Drugs.

April 6, 2001

In Brief: NCAB Still Without New Appinees As Carter, Califano Delay Drags On; Keele to U. Kansas

January 19, 1979